Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907290 · ClinicalTrials.gov registry record · Phase 2
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
A Phase 2 study of Chronic Hepatitis D Infection, sponsored by Mirum Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06907290: Active Phase 2 study of Chronic Hepatitis D Infection, sponsored by Mirum Pharmaceuticals.
NCT06907290 is a Phase 2 study of Chronic Hepatitis D Infection that is active but no longer recruiting, run by Mirum Pharmaceuticals. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06907290, a Phase 2 study of Chronic Hepatitis D Infection, is active but no longer recruiting, sponsored by Mirum Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participants will complete the same visits and assessments as those randomized to initiate brelovitug immediately. At the completion of 24-week delayed treatment period, all participants will start treatment with brelovitug.
Primary Outcome
Achieving composite endpoint defined as virologic response (undetectable HDV RNA or decline in HDV RNA ≥2 log10 IU/mL) and ALT normalization
Conditions Studied
Interventions
- DRUG Brelovitug 300 mg
- DRUG Brelovitug 900 mg
- DRUG Delayed Treatment with Brelovitug 300mg
Study Locations (20)
California
- 247 Garden Grove - Garden Grove
- 242 Huntington Beach - Huntington Beach
- 252 Long Beach - Long Beach
- 244 Los Angeles - Los Angeles
New York
- 245 New York - New York
- 256 New York - New York
- 253 New York - New York
- 255 New York - New York
Other
- 101 Camperdown - Camperdown
- 104 Liverpool - Liverpool
- 705 Plovdiv - Plovdiv
Florida
- 250 Miami - Miami
Illinois
- 251, Illinois - Chicago
Iowa
- 248 Lowa - Cities in Iowa
Maryland
- 254 Baltimore - Baltimore
Massachusetts
- 241, Massachusetts - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
What the registry record for NCT06907290 still lists
NCT06907290 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Chronic Hepatitis D Infection appearing as the primary indexed condition, and to 3 interventions - of which Brelovitug 300 mg is the first listed.
NCT06907290 names 20 study sites across 12 states, led by California, New York, Other.
Frequently Asked Questions
What is clinical trial NCT06907290 about?
NCT06907290 is a clinical study titled "A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection". This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection. The comparator in this study will be 24-weeks of delayed treatment. During the 24-weeks of delayed treatment, participa...
What is the current status of trial NCT06907290?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2025-03-25. Estimated completion is 2029-09.
What conditions does trial NCT06907290 study?
This clinical trial studies the following conditions: Chronic Hepatitis D Infection.
What interventions are being tested in trial NCT06907290?
The interventions under investigation include: Brelovitug 300 mg (DRUG), Brelovitug 900 mg (DRUG), Delayed Treatment with Brelovitug 300mg (DRUG).
Who is sponsoring clinical trial NCT06907290?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06907290 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Hepatitis D Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06907290's enrollment target sits among peer trials
150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI